Insight journal - Deals and alliances

Current Agreements Deals Update: July 2011

Posted on 06 July 2011

Tags:

Welcome to the July 2011 edition of Current Agreements Deals Update

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in June 2011.

Deal of the month

Licensing agreement for ALS-2200 and ALS-2158
Alios Biopharma, Vertex - June 13, 2011

Exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

Breaking news...

Collaborative R&D agreement for RX-04 antibiotics
Sanofi, Rib-X - Jul 6, 2011

Licensing agreement for EML4 anaplastic lymphoma kinase patent estate
Pfizer, Cell Signaling Technology - July 5, 2011

For more breaking deals as they are announced, visit:
http://www.currentagreements.com

What's new...

New flexible subscription options now available

Current Agreements is now available on a number of flexible subscription options - fees from $1,000 for a single user.

For further details of What's new at Current Agreements, visit here.

Month In Review

Welcome to the July 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in June 2011.

As we move into summer, partnering activity appears to continue at a good pace. A total of 291 partnering deals were announced during the month, with the top deal by value being the Licensing agreement for ALS-2200 and ALS-2158 signed by Alios and Vertex . The deal had a headline value of USD1,525 million.
Further details can be viewed here.

M&A also saw significant activity with 45 deals announced, with the leading deal being the acquisition of Astra Tech by Dentsply from AstraZeneca for USD1.8 billion. Full details here.

With the emerging role of personalized medicine in recent dealmaking we have published a series of reports:

Personalized Medicine Partnering Terms and Agreements

Biomarker Partnering Terms and Agreements

Companion Diagnostics Partnering Terms and Agreements

Pharmacogenomic Partnering Terms and Agreements

To see the leading deals of 2011 so far, view the set of Scorecards for 2011:

Top partnering deals 2011

Top M&A deals 2011

- check them out.

Finally, we have recently introduced new, flexible subscription options. You can now subscribe to Current Agreements for as little at USD500.
View full subscription options.

We welcome your comments and feedback on this newsletter. We also welcome contact from any company that has a deal not already announced by press release, allowing us to add non-publicized deals to the database.

Regards

Steve Poile

The Top Ten

The following are the top 10 partnering deals and alliances by value, as announced in June 2011.

1. Licensing agreement for ALS-2200 and ALS-2158 - Alios, Vertex - USD1,525 million

2. Development and licensing agreement for Enbrel biosimilar - Merck, Hanwha Chemical - USD720 million

3. Royalty financing agreement for dipeptidyl peptidase IV (DPP-IV) inhibitors - Prosidion, Royalty Pharma - USD609 million

4. Collaborative R&D and licensing agreement for ZP2929 - Boehringer Ingelheim, Zealand Pharma - USD530 million

5. Development and licensing agreement for BT-061 - Abbott, Biotest - USD470 million

6. Development and licensing agreement for oral compounds targeting P2X7 receptors - Merck Serono, Affectis - USD408 million

7. Asset purchase agreement for drug delivery technologies - proposed - Spencer Pharmaceutical, Hail First Pharma - USD250 million

8. Development and licensing agreement for oral and IV PARP inhibitor PF-01367338 - Pfizer, Clovis Oncology - USD225 million

9. Collaborative R&D agreement for drug development - China Government, United Kingdom Government - USD155 million

10. Licensing agreement for Silenor (doxepin) - Paladin Labs, Somaxon - USD134 million

Full details of each deal available at Current Agreements*
*Subscription required

Bigpharma Partnering

June saw 36 partnering deals announced where bigpharma were at least one of the parties to the deal. This is up from the 34 deals recorded in the previous month.

Roche and Pfizer were the most active during June, signing 7 deals each, with both signing deals with Clovis Oncology.

The lead deals for Roche were:

* Licensing, marketing and agreement for Bonvivia with Nycomed

* Co-development agreement for EGFR companion diagnostic with Clovis Oncology

The lead deal for Pfizer included:

* Research and development agreement for innovative drugs with Russia's ChemRar

* Development and licensing agreement for oral and IV PARP inhibitor PF-01367338 with Clovis Oncology

Deal Update Articles

Recent deals and alliances in life sciences - here's our take:

AstraZeneca offloads AstraTech subsidiary, gains $1.8 billion
DENTSPLY International has signed a definitive agreement to acquire Astra Tech, a leading provider of dental implant products, based in Mölndal, Sweden, from AstraZeneca for approximately $1.8 billion in cash.

Boehringer and Zealand team up to develop diabetes and obesity
therapeutics
The companies have jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

Merck strikes generic Enbrel deal with Hanwha for $720 million (link no longer available)
Bigpharma giant Merck & Co has struck a deal with South Korea's Hanwha for the development and commercialization of a generic version of Enbrel, Amgen's blockbuster arthritis treatment.

Vertex inks $1.5bn deal with Alios to mix hep C cocktails
Vertex is committing over $1.5 billion in a deal with Alios that seeks to develop "all-oral" combination regimens for the treatment of hepatitis C.

Subscribing to Current Agreements

Subscribe now

More details

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new1gif
e80banner300x150animgif
a1banner300x150animgif